Continuing the momentum - Qubit Pharmaceuticals in 2025

Welcome to the International Year of Quantum!

At Qubit Pharmaceuticals, we’re excited to embrace this global celebration of quantum science as we kick off another year of groundbreaking innovation. 2024 was a year of tremendous growth, and we’re eager to share all the exciting developments we have lined up for 2025. Here’s a glimpse of what’s already unfolding:

A Strong Presence at JPM Healthcare Conference

This January, we’re making waves at the JP Morgan Healthcare Conference, co-organizing and speaking at three impactful side events alongside some of the brightest minds in the industry.

• Next in TechBio: Organized by Integrated Biosciences Inc. and Benchling, moderated by Peter Fuchs, Chief AI Officer at Eli Lilly, our CEO Robert Marino has been invited to speak at a panel discussion on Computational Drug Discovery and Data-Driven Innovation, alongside other Biotech CEOs. This will be followed by a Fireside Chat with Karen Akinsanyan, President R&D Officer at Schr?dinger Therapeutics. Tuesday, January 14, 7pm PT For details and registration, click here
• Quantum for Pharma Breakfast Symposium: A collaboration with AWS, IonQ, and L.E.K. Consulting, featuring our CEO, Robert Marino, as a speaker. Wednesday, January 15, 8:30am PT For details and registration, click here
• Models on (AI) Models: Our new Chief Corporate Development Officer, Andrea De Souza, has been invited to speak at this innovative event, bringing together pharma, biotech, software, and government perspectives on the business models that drive success for AI-related biotech. Wednesday, January 15, 8pm PT

From exploring the intersection of quantum computing and AI to shaping the future of drug discovery, it’s shaping up to be a week filled with insightful discussions, collaboration opportunities, and meaningful connections.

You’re in San Francisco? Let’s meet—reach out to us and we’ll make it happen!

Celebrating Our Recognition

We're proud to share that Qubit Pharmaceuticals has been named a Technology Pioneer 2024 by the World Economic Forum—an honor that highlights our role in shaping the future of healthcare with quantum technology. Additionally, we were selected as an official nominee for the Prix Galien USA 2024 in the Best Startup category, which anyone familiar with the pharma industry will recognise as great achievement. These accolades reflect our commitment to advancing innovation and excellence in the field of drug discovery.

Pioneering Research: Shaping the Future of Drug Discovery & Quantum Computing Applied to Quantum Chemistry

At Qubit Pharmaceuticals, our mission is clear: unlock the potential of quantum at scale to design better treatments for any target and every patient—redefining drug discovery through quantum innovation. Over the past year, we’ve published transformative research - imagine, 13 articles published or submitted to preprint - sets the foundation for future breakthroughs. Here's a selection of the latest papers in 2024.

The Latest 2024 Highlights:

• Polylogarithmic-depth controlled-NOT gates without ancilla qubits: This paper introduces a novel quantum computing approach that could significantly impact future quantum algorithms by reducing complexity without needing additional qubits. Published in Nature Communications - read the article here, or check our “Behind the paper” post on the Nature Physics community!
• Velocity Jump Langevin Process: A hybrid method combining classical and quantum approaches to accelerate molecular simulations without compromising accuracy. As well as its companion paper: "Velocity Jumps for Molecular Dynamics" detailing the JUMP approach, a new class of molecular dynamics integrators that combines classical Langevin diffusion with a piecewise deterministic Markov process. Read here and here !
• Shortcut to Chemically Accurate Quantum Computing: An innovative approach using density-based corrections to achieve unprecedented precision with fewer quantum resources. Available in Communications Chemistry from the Nature Portfolio - read here or check out the blog!

Starting Off Big - Our First Paper of 2025:

We just celebrated the publication of “Quantum Speedup for Nonreversible Markov Chains”, developed in partnership with Sorbonne Université. This breakthrough focuses on nonreversible Markov chains—commonly found in biological systems—and explores how quantum computing can provide significant speedups for real-world applications, including drug discovery.

Check out the preprint here!

With these publications, we’re not just exploring possibilities—we’re laying the groundwork for tangible, life-changing solutions in drug discovery.

Advances in Our Drug Discovery Programs

Our drug discovery programs have been quietly making exciting progress as we push the boundaries of molecular design for complex targets.

• Exploring RNA as Therapeutics: We continue to advance in RNA-targeted therapies, focusing on RNA and RNA-binding protein targets in oncology and chronic immune diseases. Check out our blog to learn more about how we leverage our cutting-edge science and technologies to explore this exciting avenue! Read it here.
• Targeting KAT6A: We continue to make strides in designing inhibitors for KAT6A, a key player in oncology and a promising therapeutic target. Want to learn more? Reach out to us now or meet us at the JPM Conference, Davos, or any milestone event this year!

Stay tuned as we reveal more about the scientific advancements driving these programs in 2025.

Let's meet in Davos!

Did they just say Davos? Yes indeed! Next week, we’ll take the stage at unDavos summit in Davos, joining global leaders to discuss the transformative potential of quantum science in healthcare at a panel discussions titled Quantum Ready: The Business Opportunity. For additional information click here.

• Tuesday, January 21, 11 am CET, Mountain Plaza hotel

In 2024, we were honored to be part of the French President's delegation, having the incredible opportunity to meet with global leaders, key decision makers, and the most innovative biotech and techbio companies. We remain committed to contributing to the global conversation on innovation, sustainability, and scientific excellence, and would be delighted to meet with you there.

?? Reach out to set a date for a meeting!

Looking Back and Moving Forward

Reflecting on 2024, we traveled the world to share our vision for quantum-aided drug discovery. From conferences to collaborations, it was a year of meaningful milestones. Check out our LinkedIn posts for more details about the destinations and discussions that shaped our journey, the research that has driven us, and accelerated our growth. The International Year of Quantum provides the perfect backdrop for everything we have in store for 2025. From groundbreaking research to fostering new collaborations, we’re more inspired than ever to push boundaries and deliver quantum-powered solutions that transform drug discovery.

?? Subscribe to our newsletter and follow us on LinkedIn to stay connected and be the first to hear our latest updates.

?? Reach out to our team to explore how we can work together to unlock the future of drug discovery.